Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218397 · ClinicalTrials.gov registry record · NA
Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 500
- Enrollment target
NCT03218397: Completed NA study, sponsored by Duke University.
NCT03218397 is a NA study that has completed, run by Duke University. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03218397, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
Study Summary
RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1. Standard culture and antimicrobial susceptibility testing (AST); or 2. Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
Primary Outcome
Mean hours until first modification of antibiotic therapy within 72 hours post randomization
Interventions
- DEVICE Accelerate PhenoTest™ BC Kit
- DEVICE Standard Culture and AST
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2018-11-30 |
| Phase | NA |
What the finished NCT03218397 record still lists
NCT03218397 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Accelerate PhenoTest™ BC Kit is the first listed.
NCT03218397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03218397 about?
NCT03218397 is a clinical study titled "Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia". RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1. Standard culture and antimicrobial susceptibility testing (AST); or 2. Rapid identification and AST using the Accelerat...
What is the current status of trial NCT03218397?
This trial is currently completed. It is a NA study. The enrollment target is 500 participants. The study started on 2017-10-09. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03218397?
The interventions under investigation include: Accelerate PhenoTest™ BC Kit (DEVICE), Standard Culture and AST (DEVICE).
Who is sponsoring clinical trial NCT03218397?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03218397's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI